1 / 17

Drug appraisal organisations: A comparison of SMC and NICE

Drug appraisal organisations: A comparison of SMC and NICE. John Ford, University of Aberdeen Norman Waugh, Warwick Evidence Pawana Sharma, University of Aberdeen Mark Sculpher , University of York Andrew Walker, University of Glasgow. Scottish Medicine Consortium (SMC).

holland
Download Presentation

Drug appraisal organisations: A comparison of SMC and NICE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug appraisal organisations: A comparison of SMC and NICE John Ford, University of Aberdeen Norman Waugh, Warwick Evidence Pawana Sharma, University of Aberdeen Mark Sculpher, University of York Andrew Walker, University of Glasgow

  2. Scottish Medicine Consortium (SMC) • Established in 2001 • All newly licensed medications • Main submission from manufacturer

  3. National Institute of Health and Clinical Excellence (NICE) • Only medications referred from Department of Health • Pre-2005 • Technology Assessment Reports (TAR) • Post-2005 • Single technology appraisal (STA) • Multiple technology appraisal (MTA) • Various controversies

  4. Our study • What is the difference in recommendations and timelines between NICE and SMC? • Has the introduction of the STA system led to speedier guidance?

  5. Methods • Drug specific approach • All medications until Aug 2010 included • Time • from marketing authorisation (MA) to guidance publication • Appraisal outcomes • As defined by SMC or NICE

  6. Drug demographics • 140 drugs included • 57 cancer related • 415 by SMC alone • 45 cancer related • 102 by NICE • 27 cancer related

  7. Recommendations

  8. Recommendations

  9. Reason for differences in recommendation • Occasionally NICE allows cost per QALY >£30,000 • Timings of appraisals may differ • Manufacturers’ submission may not be the same • Longer appraisals

  10. Timelines (all drugs)

  11. Reasons for differences in timelines • Consultation • Number of stakeholders • Size differences • Legal challenge? • Transparency • Final report

  12. Timelines (cancer drugs)

  13. Reasons for differences in cancer drugs • Evidence base may be uncertain • Cost per QALY likely to be borderline

  14. Discussion • Trade-off between transparency, consultation and timeliness • How many drug appraisal bodies does the UK need?

  15. Conclusion • Small difference in recommendations between SMC and NICE • SMC is considerable speedier than NICE • STA system has led to speedier decisions, but not for cancer drugs • Increased time is probably due to consultation and transparency

  16. Any questions?

More Related